Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Conmed (CNMD) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Conmed (CNMD) over the last 16 years, with Q4 2025 value amounting to $5.1 million.

  • Conmed's Capital Expenditures rose 2650.99% to $5.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was $19.8 million, marking a year-over-year increase of 5137.57%. This contributed to the annual value of $19.8 million for FY2025, which is 5137.57% up from last year.
  • Per Conmed's latest filing, its Capital Expenditures stood at $5.1 million for Q4 2025, which was up 2650.99% from $5.2 million recorded in Q3 2025.
  • Over the past 5 years, Conmed's Capital Expenditures peaked at $6.7 million during Q3 2022, and registered a low of $2.0 million during Q1 2024.
  • In the last 5 years, Conmed's Capital Expenditures had a median value of $4.4 million in 2023 and averaged $4.4 million.
  • In the last 5 years, Conmed's Capital Expenditures skyrocketed by 9074.82% in 2022 and then crashed by 5216.27% in 2024.
  • Over the past 5 years, Conmed's Capital Expenditures (Quarter) stood at $3.2 million in 2021, then surged by 78.04% to $5.7 million in 2022, then decreased by 14.46% to $4.9 million in 2023, then fell by 16.79% to $4.0 million in 2024, then grew by 26.51% to $5.1 million in 2025.
  • Its last three reported values are $5.1 million in Q4 2025, $5.2 million for Q3 2025, and $5.7 million during Q2 2025.